Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Omniome, founded in 2013 and based in San Diego, California, is a biotechnology company specializing in DNA sequencing technology. The company has developed a proprietary platform that offers both long-read and short-read sequencing capabilities, along with software and bioinformatics tools for data analysis. Omniome's products serve various sectors, including human genomics, plant and animal genomics, microbial genomics, and cancer research.
Since its inception, Omniome has made significant strides in the biotechnology industry, raising a total of $128.63 million in funding. This substantial investment demonstrates the confidence of investors in Omniome's innovative approach to DNA sequencing and its potential impact on genomic research.
A notable development in Omniome's journey occurred in July 2021 when the company was acquired by PacBio at a valuation between $600 million and $800 million. This acquisition marks a significant milestone for Omniome and underscores the value of its technology in the competitive genomics market.
Given Omniome's current status as a subsidiary of PacBio, there are no concrete plans or public announcements regarding an initial public offering (IPO) for Omniome as an independent entity. The company's future in the public markets will likely be tied to PacBio's strategic decisions and overall market conditions in the biotechnology sector.
Investors interested in gaining exposure to Omniome's technology and potential may consider exploring investment opportunities in its parent company, PacBio, which is publicly traded. However, it's important to note that investing in any company carries risks, and potential investors should conduct thorough research and consult with financial advisors before making investment decisions.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Omniome's IPO prospects remain uncertain, investors eager to gain exposure to innovative biotech companies don't have to wait. At Linqto, we offer members access to interests in pre-IPO private companies, including potential leaders in the genomics and sequencing technology sectors. Our platform allows you to diversify your portfolio with lower minimum investments in promising companies like Omniome, potentially benefiting from their growth before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
